---
schema_version: "secwatch.filing_event.v1"
accession: "0001703057-26-000035"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2026-06-17T16:38:25+00:00"
generated_at: "2026-06-17T16:39:11.902203+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AbCellera announces $56M upfront collaboration with Jazz Pharma for T-cell engager antibodies

## Summary
- $56M upfront for first two programs; $28M additional upon initiation of third program within 12 months.
- Up to $792M per program in option fees and milestones plus mid-single to low-double-digit royalties on net sales.
- Collaboration targets gastrointestinal cancers and other solid tumors using AbCellera's T-cell engaging multispecific platform.
- Jazz holds exclusive worldwide rights to develop and commercialize after exercising option for each program.
- AbCellera may also conduct IND-enabling studies and manufacture clinical supply for programs under the collaboration.

## SEC filing metadata
- accession: 0001703057-26-000035
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2026-06-17T16:38:25+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000035/0001703057-26-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000035/abcl-20260617.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001703057-26-000035
- JSON: https://secwatch.observer/filing/0001703057-26-000035.json
- Plain text: https://secwatch.observer/filing/0001703057-26-000035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.